89Zr-Rituximab

N/A

Report date: 2025/11/18 17:45:22

Base Information

Drug Name89Zr-Rituximab

Drug Alias Name89Zirconium-rituximab

ClassificationRadiation-emitting products > Nuclides > Zirconium > 89ZrRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionAnti-CD20

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsCentral Nervous System Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNetherlands

CombinationsNo

Global Highest StatusClinical

Highest Status in ChinaN/A

Originator CompaniesUniversitair Medisch Centrum Utrecht

China Registration ClassN/A

Develop Information

Active CompaniesUniversitair Medisch Centrum Utrecht

Inactive CompaniesN/A

Active IndicationsCentral Nervous System Lymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A